Inflammatory bowel diseases (IBDs) are caused by an aberrant and excessive local immune response to components of the bacterial microflora that are: poorly controlled by endogenous counter regulatory mechanisms such as the immunosuppressive cytokine transforming growth factor-beta 1 (TGF-beta 1). Studies in human IBD tissues have documented a disruption of TGF-beta 1 signaling marked by a block in the phosphorylation of the activated TGF-beta receptor-associated signaling molecule, Smad3, caused by the upregulation of the intracellular inhibitor of Smad signaling, Smad7. Inhibition of Smad7 with a specific antisense oligonucleotide restores TGF-beta 1/Smad3 signaling, resulting in a marked suppression of inflammatory cytokine production. The functional relevance of Smad7 in gut inflammation was confirmed by studies in murine models of IBD. In inflamed tissues of mice with colitis induced by either the trinitrobenzene sulfonic acid or oxazolone, p-Smad3 was low despite active TGF-beta 1 being produced in excess. In vivo administration of Smad7 antisense oligonucleotides to mice with colitis restored TGF-beta 1 signaling and decreased the synthesis of inflammatory molecules and the extent of gut damage. These data support a role for Smad7 in maintaining intestinal inflammation, and suggest that blocking Smad7 could be a promising way to dampen the ongoing inflammation in IBD.

Monteleone, G., Boirivant, M., Pallone, F., Macdonald, T.t. (2008). TGF-beta 1 and Smad7 in the regulation of IBD. In Mucosal Immunology (pp.S50-S53). NEW YORK : NATURE PUBLISHING GROUP [10.1038/mi.2008.55].

TGF-beta 1 and Smad7 in the regulation of IBD

MONTELEONE, GIOVANNI;PALLONE, FRANCESCO;
2008-01-01

Abstract

Inflammatory bowel diseases (IBDs) are caused by an aberrant and excessive local immune response to components of the bacterial microflora that are: poorly controlled by endogenous counter regulatory mechanisms such as the immunosuppressive cytokine transforming growth factor-beta 1 (TGF-beta 1). Studies in human IBD tissues have documented a disruption of TGF-beta 1 signaling marked by a block in the phosphorylation of the activated TGF-beta receptor-associated signaling molecule, Smad3, caused by the upregulation of the intracellular inhibitor of Smad signaling, Smad7. Inhibition of Smad7 with a specific antisense oligonucleotide restores TGF-beta 1/Smad3 signaling, resulting in a marked suppression of inflammatory cytokine production. The functional relevance of Smad7 in gut inflammation was confirmed by studies in murine models of IBD. In inflamed tissues of mice with colitis induced by either the trinitrobenzene sulfonic acid or oxazolone, p-Smad3 was low despite active TGF-beta 1 being produced in excess. In vivo administration of Smad7 antisense oligonucleotides to mice with colitis restored TGF-beta 1 signaling and decreased the synthesis of inflammatory molecules and the extent of gut damage. These data support a role for Smad7 in maintaining intestinal inflammation, and suggest that blocking Smad7 could be a promising way to dampen the ongoing inflammation in IBD.
Workshop on Mechanisms of Intestinal Inflammation
Dresden, GERMANY
OCT, 2007
Falk Fdn
Rilevanza internazionale
2008
Settore MED/12 - GASTROENTEROLOGIA
English
antisense oligonucleotide; immunoglobulin enhancer binding protein; Smad2 protein; Smad3 protein; Smad6 protein; Smad7 protein; transforming growth factor beta1; biological marker; antiinflammatory activity; colitis; Crohn disease; cytokine production; digestive system inflammation; enteritis; human; immune response; mucosa inflammation; nonhuman; priority journal; protein phosphorylation; regulatory mechanism; review; signal transduction; ulcerative colitis; upregulation; animal; disease model; immunology; metabolism; Animals; Biological Markers; Disease Models, Animal; Humans; Inflammatory Bowel Diseases; Signal Transduction; Smad7 Protein; Transforming Growth Factor beta1
Intervento a convegno
Monteleone, G., Boirivant, M., Pallone, F., Macdonald, T.t. (2008). TGF-beta 1 and Smad7 in the regulation of IBD. In Mucosal Immunology (pp.S50-S53). NEW YORK : NATURE PUBLISHING GROUP [10.1038/mi.2008.55].
Monteleone, G; Boirivant, M; Pallone, F; Macdonald, Tt
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/28768
Citazioni
  • ???jsp.display-item.citation.pmc??? 50
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 92
social impact